Medications

First cell-based gene therapy approved for multiple myeloma

Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday.

Oncology & Cancer

A leap forward in research on CAR T cell therapy

In cancer immunotherapy, cells in the patient's own immune system are activated to attack cancer cells. CAR T cell therapy has been one of the most significant recent advances in immunotherapies targeted at cancer.

page 1 from 5